Lanthanum Carbonate (Fosrenol, BAY77-1931)
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, Kidney Disease
Trial Timeline
Oct 10, 2013 โ Aug 5, 2016
NCT ID
NCT01955876About Lanthanum Carbonate (Fosrenol, BAY77-1931)
Lanthanum Carbonate (Fosrenol, BAY77-1931) is a pre-clinical stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01955876. Target conditions include Hyperphosphatemia, Kidney Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01955876 | Pre-clinical | Completed |
Competing Products
20 competing products in Hyperphosphatemia